Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ZILA -- Ignore unavailable to you. Want to Upgrade?

To: J. Kittle who wrote (883)	1/25/2000 8:08:00 AM
From: BlueCheap	Respond to of 897

(PR NEWSWIRE) Inter-Cal's L. Phillips Brown, DVM, to Focus on Ester-C Animal Inter-Cal's L. Phillips Brown, DVM, to Focus on Ester-C Animal Market PRESCOTT, Ariz., Jan. 25 /PRNewswire/ -- The Inter-Cal subsidiary of Oxycal Laboratories, a Zila company (Nasdaq: ZILA) and developer of value-added ingredients and technologies for the global nutritional and natural products industries, announced that L. Phillips Brown, DVM, has been promoted to the newly created position of Animal Products Manager. Dr. Brown will focus on building Inter-Cal's presence in the animal and veterinary markets. "In view of the dramatic clinical evidence of the effectiveness of Ester-C(R) mineral ascorbates in dogs, horses and other large animals, we believe there is a significant market opportunity for Inter-Cal's patented Ester-C vitamin products in animal health maintenance and care," said Inter-Cal Vice President & General Manager Michelle Michels. "Dr. Brown has produced an exceptional record of success as Inter-Cal's Business Development and Marketing Manager for our broad and expanding lines of vitamin and botanical products," Michels said. "By focusing his efforts on the growing animal nutrition market, we believe Inter-Cal can build a substantial new revenue stream." Products containing Ester-C mineral ascorbate are sold in the U.S., Canada and 41 other countries. The ingredient, which has been one of the top selling forms of vitamin C in health and natural product stores the last four years, is used in supplements for humans and animals, functional foods and beverages, and sports performance products. Additional information on Ester-C products is available at www.intercal.com. Zila, Inc., has three operating groups. The Pharmaceuticals/Biomedical Group includes: Zila Pharmaceuticals, marketer of prescription and non-prescription oral healthcare products; Zila Biomedical, developer of OraTest(R) oral cancer detection products; and Zila Biotech, producer of the only pharmaceutical-grade toluidine blue - Zila(R) Tolonium Chloride. The Professional Products Group includes Zila Dental Supply, a national dental supplies distributor. The Nutraceuticals Group includes Oxycal Laboratories and its Inter-Cal subsidiary, manufacturer and supplier of value-added ingredients, including patented Ester-C(R) branded products and botanicals such as Palmettx(TM) saw palmetto extract, for the global nutritional industry. Information is available at www.zila.com. This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs. Included among the factors affecting Inter-Cal's nutritional ingredients are levels of acceptance among consumers, the outcome of on-going research on vitamin C and Ester-C mineral ascorbates, and regulation of the markets in which nutritional supplements are sold. There can be no assurance that the forward-looking statements contained in this document will, in fact, transpire or prove to be accurate. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to Zila's annual report on Form 10-K for its fiscal year ended July 31, 1999 filed with the Securities and Exchange Commission. SOURCE Inter-Cal -0- 01/25/2000 /CONTACT: Michelle Michels of Inter-Cal, 520-445-8063/ /Web site: zila.com /Web site: intercal.com (ZILA)